Zevra Therapeutics, Inc. Common Stock (ZVRA) Stock
NASDAQ · ZVRA
11.04
Fundamentals
Market cap
$655.60M
Price / Earnings ratio
11.5x
Price / Sales ratio
4.9x
Price / Book ratio
3.1x
Return on assets
46.0%
Ex-Dividend date
N/A
Last payment date
N/A
Dividend amount
$0.00
Dividend yield
0.00%
Debt / Equity ratio
N/A
Recent news

MarketBeat
Zevra Therapeutics Q2 Earnings Call Highlights
NeutralZVRAAugust 6, 2026
MarketBeatNeutral
Zevra Therapeutics Q2 Earnings Call Highlights
ZVRA

Zacks Investment Research
Zevra Therapeutics (ZVRA) Q2 Earnings and Revenues Surpass Estimates
NeutralZVRAAugust 6, 2026
Zacks Investment ResearchNeutral
Zevra Therapeutics (ZVRA) Q2 Earnings and Revenues Surpass Estimates
ZVRA

Business Wire
ZVRA Investor Alert: Levi & Korsinsky Notifies Investors of Investigation Into Zevra Therapeutics (ZVRA)
NeutralZVRAJuly 29, 2026
Business WireNeutral
ZVRA Investor Alert: Levi & Korsinsky Notifies Investors of Investigation Into Zevra Therapeutics (ZVRA)
ZVRA

Business Wire
ZVRA Investors Have Opportunity to Join Zevra Therapeutics, Inc. Fraud Investigation with SBS Law
NeutralZVRAJuly 28, 2026
Business WireNeutral
ZVRA Investors Have Opportunity to Join Zevra Therapeutics, Inc. Fraud Investigation with SBS Law
ZVRA
Technicals
OscillatorsSell5 Indicators
Moving AveragesStrong Sell12 Indicators
Analyst Ratings
Strong Sell0
Sell0
Neutral0
Buy5
Strong Buy0
Financials
Performance
Revenue
Net income
Net margin %
2025
128M84M42M0
Debt & Balance Sheet
Total assets
Total liabilities
2025
342M226M113M0
Revenue to Profit
2025$106.5M
Revenue$0.0
Cost of revenue$0.0
Gross profit$0.0
Operating expenses$83.2M
Net incomeEarnings
EPS forecast
Actual EPS
$0.05
Q4FY25
$0.11
Q1FY26
$0.15
Q2FY26
The market is expecting earnings per share of $0.15 for this quarter. The company has not yet shared when it is announcing earnings.
% positive news of 10 articles
published over the past 14 days
Latest news

MarketBeat
Zevra Therapeutics Q2 Earnings Call Highlights
NeutralZVRAAugust 6, 2026
MarketBeatNeutral
Zevra Therapeutics Q2 Earnings Call Highlights
ZVRA

Zacks Investment Research
Zevra Therapeutics (ZVRA) Q2 Earnings and Revenues Surpass Estimates
NeutralZVRAAugust 6, 2026
Zacks Investment ResearchNeutral
Zevra Therapeutics (ZVRA) Q2 Earnings and Revenues Surpass Estimates
ZVRA

Business Wire
ZVRA Investor Alert: Levi & Korsinsky Notifies Investors of Investigation Into Zevra Therapeutics (ZVRA)
NeutralZVRAJuly 29, 2026
Business WireNeutral
ZVRA Investor Alert: Levi & Korsinsky Notifies Investors of Investigation Into Zevra Therapeutics (ZVRA)
ZVRA

Business Wire
ZVRA Investors Have Opportunity to Join Zevra Therapeutics, Inc. Fraud Investigation with SBS Law
NeutralZVRAJuly 28, 2026
Business WireNeutral
ZVRA Investors Have Opportunity to Join Zevra Therapeutics, Inc. Fraud Investigation with SBS Law
ZVRA

Stocktwits
ZVRA Stock Sinks 23% On EU Setback — Analyst Says Risk Is ‘A Headwind, But Not Insurmountable’
NeutralZVRAJuly 24, 2026
StocktwitsNeutral
ZVRA Stock Sinks 23% On EU Setback — Analyst Says Risk Is ‘A Headwind, But Not Insurmountable’
ZVRA

Stocktwits
ZVRA Stock Plummets Pre-Market, Heads For Worst Day In Over 5 Years – What’s Driving The Sell-Off?
NeutralZVRAJuly 24, 2026
StocktwitsNeutral
ZVRA Stock Plummets Pre-Market, Heads For Worst Day In Over 5 Years – What’s Driving The Sell-Off?
ZVRA

Stocktwits
ZVRA Stock Hits Its Highest Levels In Nearly 5 Years – What’s Driving This Sharp Rally Today?
NeutralZVRAJune 9, 2026
StocktwitsNeutral
ZVRA Stock Hits Its Highest Levels In Nearly 5 Years – What’s Driving This Sharp Rally Today?
ZVRA

Stocktwits
ZVRA Stock ‘Way Undervalued’? Analyst Sees 117% Upside After Patent Extends Exclusivity Till 2041 For Sole Approved Drug
NeutralZVRAJune 8, 2026
StocktwitsNeutral
ZVRA Stock ‘Way Undervalued’? Analyst Sees 117% Upside After Patent Extends Exclusivity Till 2041 For Sole Approved Drug
ZVRA

Proactive Investors
Zevra Therapeutics extends MIPLYFFA exclusivity to 2041
NeutralZVRAJune 8, 2026
Proactive InvestorsNeutral
Zevra Therapeutics extends MIPLYFFA exclusivity to 2041
ZVRA

Zacks Investment Research
Zevra Therapeutics (ZVRA) Q1 Earnings and Revenues Surpass Estimates
NeutralZVRAMay 6, 2026
Zacks Investment ResearchNeutral
Zevra Therapeutics (ZVRA) Q1 Earnings and Revenues Surpass Estimates
ZVRA
About Zevra Therapeutics, Inc. Common Stock
No description available.
SectorHealthcare
IndustryBiotechnology
Employees61
CEOMr. Neil F. McFarlane
IPO DateApr 16, 2015
HeadquartersBoston, MA
Key Executives
| Name | Title | Year Born |
|---|---|---|
| Mr. Neil F. McFarlane | President, CEO & Director | 1973 |
| Mr. Rahsaan W. Thompson J.D. | Chief Legal Officer, Secretary & Compliance Officer | 1971 |
| Mr. Justin A. Renz CPA, MBA | CFO & Treasurer | 1972 |
| Ms. Nichol L. Ochsner | Vice President of Investor Relations & Corporate Communications | — |
| Ms. Alison Peters | Chief People Officer | — |
| Dr. Christopher M. Lauderback Ph.D. | Senior Vice President of Manufacturing | 1975 |
| Mr. Joshua M. Schafer M.B.A., M.S. | Chief Commercial Officer | 1972 |
| Dr. Adrian Quartel FFPM, M.D. | Consultant | 1961 |
| Mr. Gerald J. Orehostky | Senior Vice President of Regulatory Affairs & Quality | 1967 |
| Ms. Tanya Hayden | Senior VP & Chief of Staff | 1980 |
Fundamentals
Valuation
Market cap$655.60M
Price-to-sales ratio4.91
Price-to-book value3.07
Price-earnings ratio11.50
Return on Equity81.00%
Return on Sales115.00%
Return on Assets46.00%
PEG ratio10.67
Earnings Per Share
Earnings Per Share$0.95
Income Statement
Average volume868,897
EBITDA$144.61M
1 year high (52w)$15.04
1 year low (52w)$8.01
Dividend
Ex dividend dateN/A
Dividend amount$0.00
Dividend yield0.00%
Last payment dateN/A
Dividend yield (TTM)N/A
Next earnings reportN/A
Solvency
Debt-to-equity ratioN/A
Technicals
OscillatorsSell5 Indicators
Moving AveragesStrong Sell12 Indicators
What the experts say
5 Wall Street Analyst Ratings
BUY
100% Buy
0% Hold
0% Sell
Target price
$24.20
Est return
116.65%
Seasonality
Monthly price change (%)| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2023 | +0.7 | -2.7 | -4.4 | -0.4 | -3.9 | +3.5 | -10.4 | -5.1 | +7.0 | +32.1 | ||
| 2024 | -15.2 | +13.1 | -18.1 | -11.2 | +1.1 | +0.4 | +43.9 | +21.4 | -4.9 | +19.0 | +11.1 | -13.8 |
| 2025 | -10.5 | +4.7 | +2.2 | +0.1 | +11.9 | +1.7 | +24.1 | -18.4 | +4.5 | +8.0 | -17.4 | +7.4 |
| 2026 | +7.9 | -4.6 | +2.5 | +8.1 | +15.1 | +24.8 | -31.1 | +16.7 | -8.5 |



